무표지 검출(LFD) 시장은 2024-2031년간9.8%의 연평균 복합 성장률(CAGR)로 2031년까지 44억 8,000만 달러에 달할 것으로 예측됩니다.
이 보고서는 광범위한 2차 및 1차 조사, 시장 시나리오에 대한 심층 분석, 주요 시장 성장 촉진요인, 억제요인, 과제 및 기회 분석으로 구성되어 있습니다. 이러한 성장은 제약 및 생명공학 시장의 고성장, 정부 이니셔티브, 연구 개발 자금 증가, 신약 개발에 대한 혁신적 접근 방식 채택 증가에 기인합니다. 그러나 높은 장비 비용과 복잡한 장비를 다룰 수 있는 숙련된 전문가의 부족은 이 시장의 성장을 저해하는 요인으로 작용하고 있습니다.
또한, 비표지 검출의 기술 발전, PoC 검사에서 비표지 검출의 적용 확대, 신흥국에서의 비표지 검출은 이 시장에서 사업을 운영하는 기업들에게 성장 기회를 제공할 것으로 예상됩니다. 그러나 저질량 저분자를 실시간으로 검출하기 위한 과제와 민감도 및 특이도의 한계는 시장 성장에 영향을 미칠 수 있는 주요 과제입니다.
(주 : 주요 5개사의 SWOT 분석을 게재)
Label-free Detection Market Size, Share, Forecast, & Trends Analysis by Product (Biosensor, Microplate, Microcalorimeter), Technology (SPR, BLI), Process (Binding Kinetic, Lead Generation, Hit Confirmation), Application, End User-Global Forecast to 2031
The label-free detection market is projected to reach $4.48 billion by 2031 at a CAGR of 9.8 % from 2024 to 2031.
Succeeding extensive secondary and primary research and in-depth analysis of the market scenario, the report comprises the analysis of key industry drivers, restraints, challenges, and opportunities. This growth is due to high growth in the pharmaceutical & biotechnology market, government initiatives, rising R&D funding, and increasing adoption of innovative approaches in drug discovery. However, the high cost of instruments and shortage of skilled professionals to handle complex equipment restrain the growth of this market.
Furthermore, the technological advancements in label-free detection, growing applications of label-free detection in point-of-care testing, and emerging economies are expected to generate growth opportunities for the players operating in this market. However, the challenges of detecting low-mass small molecules in real time and limited sensitivity & specificity are major challenges impacting market growth.
The report offers a competitive landscape based on an extensive assessment of the product portfolio offerings, geographic presences, and key strategic developments adopted by leading market players in the industry over four years (2021-2024). The key players operating in the label-free detection market are Danaher Corporation (U.S.), PerkinElmer, Inc. (U.S.), Agilent Technologies, Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), GE HealthCare Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Sartorius AG (Germany), Corning Inc. (U.S.), Horiba, Ltd. (Japan), Malvern Panalytical Ltd (U.K.), and Bruker Corporation (U.S.).
Based on product type, the market is segmented into consumables, instruments, and software. Among all the instrument types, in 2024, the optical biosensor instruments segment is expected to account for the largest share of 78.4% of the label-free detection instruments market. The large market share of this segment can be attributed to the direct and real-time measurement, in addition to multiplexing capabilities, which increases its adoption.
Among all the technologies studied in this report, in 2024, the Surface Plasmon Resonance (SPR) segment is expected to account for the larger share of the label-free detection market. The large market share of this segment can be attributed to the benefits offered by the SPR technology over the other technologies, such as real-time monitoring, requires minimal amounts of sample for experiments, high sensitivity, and provides quantitative data on binding kinetics, equilibrium constants, association, and dissociation rates, and many more are the factors contributing to the significant market share of this segment.
Among all the applications studied in this report, in 2024, the drug discovery & development segment is expected to account for the largest share of the label-free detection market. Label-free detection techniques offer high-throughput screening of various drug candidates for a wide range of target molecules and offer real-time molecular interactions. This results in improved screening of massive compound databases. The capacity to quickly identify interesting lead compounds is the factor that boosts the demand for label-free detection in drug discovery.
Among all the processes studied in this report, in 2024, the binding kinetics segment is expected to account for the largest share of the label-free detection market. The large market share of this segment can be attributed to the advancements in structural biology and the growing focus on personalized medicine. Further, to ensure efficacy and safety, biologics, including monoclonal antibodies, need to be properly characterized and tested in terms of binding kinetics. Label-free detection techniques provide a non-destructive and label-free method for examining complicated interactions, which makes them an excellent alternative for biological research.
Among all the end users studied in this report, in 2024, the pharmaceutical & biotechnology companies segment is expected to account for the largest share of the label-free detection market. The large market share of this segment can be attributed to the technological advancements that have increased the adoption of label-free technologies by the pharmaceutical & biotechnology companies, and product launches to expand the innovative offering.
An in-depth analysis of the geographical scenario of the label-free detection market provides detailed qualitative and quantitative insights into the five major geographies (North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa) along with the coverage of major countries in each region. In 2024, North America is expected to account for the largest share of over 43.6% of the label-free detection market. In the region in 2024, the U.S. is expected to account for the largest share of the label-free detection market in North America. The large share of this regional market is attributed to the presence of major label-free detection companies, increasing adoption of innovative approaches in drug discovery, and technological advancements in label-free detection technologies.
Label-free Detection Market Assessment-by Product Type
Label-free Detection Market Assessment-by Technology
Note: Other technologies include Optical Waveguide Grating Technology (OWGT), Microscale Thermophoresis (MST), and Electrical Impedance Spectroscopy (EIS).
Label-free Detection Market Assessment-by Application
Note: Other technologies include bioprocessing and impurity testing.
Label-free Detection Market Assessment-by Process
Note: Other processes include end-point screening & specificity testing and affinity analysis.
Label-free Detection Market Assessment-by End User
Label-free Detection Market Assessment-by Geography
(Note: SWOT analysis of the top 5 companies will be provided.)